Lukewarm data for Second Sight
Second Sight’s second product might lead the company to second place in the market.
Poxel tastes sweet success at last
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
Akebia plays spot the difference with investors
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
Two haemophilia A subjects help Sangamo erase 2019's losses
Promising early data with Sangamo and Pfizer’s haemophilia A gene therapy could set up a battle with Roche and Biomarin.
Galapagos flies with more Finch data
Filgotinib could be the safest Jak inhibitor yet, but Galapagos will need to make the most of this as it squares up to Abbvie.
Supernus struggles to gain attention
A phase III failure will do nothing to help Supernus’s SPN-812 compete against generic ADHD drugs.
Fibrocell gets a reality check
Promising data with Fibrocell’s epidermolysis bullosa gene therapy send the company down as funding worries kick in.
Aldeyra seeks to Alleviate worries with conjunctivitis win
Pivotal data validate Aldeyra’s lead project, reproxalap, but there are questions about a lack of dose response.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.